Ablynx
| Traded as | ABLX[1] |
|---|---|
| Industry | Biotechnology |
Key people |
Edwin Moses (CEO) |
| Website |
www |
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies.
History
In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2M was provided by Gimv.[2]
In July 2015 Merck & Co. and Ablynx expanded their 18 month old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for Ablynx.[3] In 2015, the Novo Nordisk announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.[4]
References
Further reading
- Wolfson W., Ablynx makes nanobodies from llama bodies, Chem Biol. 2006 Dec;13(12):1243-4.
- De Haard HJ, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT., Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection, J Bacteriol. 2005 Jul;187(13):4531-41.
External links
This article is issued from Wikipedia - version of the Wednesday, January 06, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.